Financials data is unavailable for this security.
View more
Year on year Sartorius Stedim Biotech SA 's revenues fell -20.53% from 3.49bn to 2.78bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 876.10m to 309.70m, a -64.65% decrease.
Gross margin | 41.82% |
---|---|
Net profit margin | 6.31% |
Operating margin | 14.43% |
Return on assets | 2.61% |
---|---|
Return on equity | 5.24% |
Return on investment | 3.04% |
More ▼
Cash flow in EURView more
In 2023, Sartorius Stedim Biotech SA increased its cash reserves by 8.87%, or 9.50m. Cash Flow from Financing totalled 1.99bn or 71.56% of revenues. In addition the company generated 746.40m in cash from operations while cash used for investing totalled 2.72bn.
Cash flow per share | 4.86 |
---|---|
Price/Cash flow per share | 38.72 |
Book value per share | 39.95 |
---|---|
Tangible book value per share | -6.88 |
More ▼
Balance sheet in EURView more
Current ratio | 1.94 |
---|---|
Quick ratio | 1.03 |
Total debt/total equity | 0.7507 |
---|---|
Total debt/total capital | 0.4266 |
More ▼
Growth rates in EUR
SmartText is unavailable
Div yield(5 year avg) | 0.30% |
---|---|
Div growth rate (5 year) | 3.90% |
Payout ratio (TTM) | 37.59% |
EPS growth(5 years) | 8.29 |
---|---|
EPS (TTM) vs TTM 1 year ago | -74.02 |
More ▼